5 hrs ago
Colorado Springs Independent
The poison in baby products
Look at the big change won earlier this year when the labels on Johnson's Baby Shampoo announced: "Improved Formula." This popular Johnson & Johnson baby product has long been advertised with the comforting slogan, "No More Tears," for the shampoo's ingredients don't sting a tiny tot's eyes.
Mon Sep 15, 2014
Lawyer grills DePuy executive over safety studies for Pinnacle hips
An executive at Johnson & Johnson's DePuy Orthopaedics Inc unit on Monday defended the company's assessment of safety risks associated with metal-on-metal Pinnacle hip implants in a Dallas court from a lawyer who said the company had neglected to perform critical safety testing. Pamela Plouhar, the worldwide vice president of clinical research at DePuy, was grilled by a lawyer for plaintiff Kathy Herlihy-Paoli during the first trial among more than 6,000 lawsuits over the Pinnacle hips that have been consolidated in Dallas federal court.
One Put, One Call Option To Know About for Johnson & Johnson
Consistently, one of the more popular stocks people enter into their stock options watchlist at Stock Options Channel is Johnson & Johnson . So this week we highlight one interesting put contract, and one interesting call contract, from the January 2017 expiration for JNJ.
Fri Sep 12, 2014
Taiwan baby products market: Johnson & Johnson and BA1 4bchen the...
These include Johnson & Johnson, BA1 4bchen, Sebamed, Chicco and Pigeon, which together accounted for 71% of total sales in 2012. International brands have a higher acceptance amongst parents.
Wed Sep 10, 2014
Jewish Hospital awarded grant to fight childhood obesity
LOUISVILLE, Ky. Jewish Hospital has received a major grant to help fight childhood obesity.
The Motley Fool
A Top Dividend Stock for Your Portfolio: Johnson & Johnson
Dividend stocks are an essential ingredient to a well-balanced portfolio. Even so, it's important to bear in mind that not all dividend stocks are created equal.
Tue Sep 09, 2014
Germany baby products market: Johnson & Johnson the leading industry...
It was followed by NestlA© Deutschland with a 15% value share, Procter & Gamble Germany & Co Operations with an 8% value share and Hipp with a 4% value share. All of the top four companies offer a wide range of attractive baby and child-specific products with competitive prices.
Bristol-Myers Needs a Healthy Growth Shot to Justify Its Valuation
With shares around $51 and down nearly 4% on the year to date, Bristol-Myers investors could have done much better elsewhere -- Johnson & Johnson , for instance. Johnson & Johnson stock has posted gains of 16% and beating the health care sector's 11% gain, according to Morningstar.
Mon Sep 08, 2014
Interesting January 2015 Stock Options for Johnson & Johnson
Consistently, one of the more popular stocks people enter into their stock options watchlist at Stock Options Channel is Johnson & Johnson . So this week we highlight one interesting put contract, and one interesting call contract, from the January 2015 expiration for JNJ.
Thu Sep 04, 2014
The Motley Fool
Bristol-Myers Squibb's Eliquis Takes Aim at Johnson & Johnson
Eliquis, a factor Xa inhibitor used by doctors to prevent blood clots in heart disease patients and patients following orthopedic surgery, is quickly gaining ground on Johnson & Johnson's Xarelto, a billion-dollar blockbuster the company rolled out in 2011. Since Eliquis sales are jumping and pose a potential threat to Johnson & Johnson's market share, let's take a closer look.
Wed Sep 03, 2014
Wall Street Journal
Johnson & Johnson to Quicken Development of Ebola Vaccine
Johnson & Johnson said Thursday it is accelerating the development of a vaccine regimen against Ebola, in an effort to help curb the virus that has overwhelmed West Africa. The regimen consists of two vaccine components from Johnson & Johnson's Crucell NV and Denmark-based biotech company Bavarian Nordic, both of which are developing vaccines against filoviruses, including Ebola.
The Washington Post
J&J Unit Ran - Amok' Marketing Pinnacle Hips, Jury Is Told
Johnson & Johnson's bid to convince doctors the metal-on-metal version of its Pinnacle hip implants were safe amounted to "marketing run amok," a lawyer told jurors in the first case over the devices to go to trial.
Tue Sep 02, 2014
Moms Shopping for Baby Gear Are Swayed by Online Recommendations
A new survey from BabyCenter finds that nearly two-thirds of upper-income millennial moms are influenced by online recommendations when shopping for baby gear.
J&J's Pinnacle Hips Face First Trial on Poisoned Patients
Johnson & Johnson , which set aside $2.5 billion last year to resolve claims that 8,000 of its artificial hips were defective, faces a new round of lawsuits over another line of hip implants blamed for poisoning patients.
Thu Aug 28, 2014
Wall Street Journal
J&J Seeks Buyer for Cordis Unit
Johnson & Johnson plans to seek a buyer for a business that makes medical devices including stents and catheters, said people familiar with the matter, the latest effort by the health care giant to pare its wide-ranging portfolio.
Why Johnson & Johnson (JNJ) Stock Is Declining Today
The FDA announced that the recall was of the most serious Class 1 category as the device can cause serious injury or death.
FDA says Johnson & Johnson recalls some jaw implants
Johnson & Johnson is recalling some lots of its implant used to correct defects of the jaw following more than a dozen cases of injury.
Jaw implants recalled
Johnson & Johnson is recalling some lots of its implant used to correct defects of the jaw, following more than a dozen cases of injury.
Frustrating Boston Scientific Is Not What the Investor Ordered
The shares peaked in January at $14.08 and have grossly underperformed its peers ever since.
Thu Aug 21, 2014
ViaCyte, Inc. (Formerly Known as Novocell, Inc.) Announces Signing Of Rights Agreement With
The agreement provides Janssen with a future right to evaluate a transaction related to the VC-01 combination product that ViaCyte is developing for type 1 diabetes.